Kinarus Therapeutics Holding AG (SIX:KNRS) is a clinical-stage pharmaceutical company focused on bringing novel treatments to patients suffering from viral, respiratory, and ophthalmic diseases. Kinarus’s unique and innovative combinatorial therapeutic candidate has broad potential to transform numerous therapeutic areas.

New dimensions toward effective therapies

Kinarus is a clinical-stage biopharmaceutical company focused on bringing novel, patient-focused treatments to those suffering from viral, respiratory, and ophthalmic diseases.

Kinarus was incorporated as a private company in Basel, Switzerland in 2017. Its therapeutic drug candidate, KIN001, consists of an advanced clinical stage p38 MAPK inhibitor, in-licensed from Roche, combined with a marketed drug, together enabling an oral, long-term effective treatment for patients suffering from diseases with serious impact on quality of life.

In September 2023, Kinarus Therapeutics Holding AG and Kinarus AG filed for bankruptcy.

On 29 January 2024, Kinarus Therapeutics Holding AG and Curatis AG, a Basel-Landschaft incorporated medicine distribution and drug development company predominantly focused on orphan/ultra-orphan diseases and specialty care diseases (“Curatis”), announced that they have entered into a transaction agreement (the "Transaction Agreement") regarding a contemplated Combination Transaction.

Under the terms of the Transaction Agreement, shareholders of Curatis shall exchange each outstanding Curatis share (the “Curatis Share”) into one newly issued Kinarus Holding share. All shareholders of Curatis shall contribute and exchange their Curatis Shares (as a contribution in kind in an ordinary capital increase of Kinarus Holding) into Consideration Shares in the context of this contemplated transaction (the "Combination Transaction" or the "Transaction").

In the context of the Combination Transaction, it is also envisaged to implement a reverse share split in the ratio 4,480:1 as well as a capital reduction. Closing of the Combination Transaction is expected around the end of April 2024.



Age-Related Macular Degeneration

> read more



Coronavirus disease 19

> read more



Idiopathic Pulmonary Fibrosis

> read more